Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results. Tania Gonsalves, Canaccord Genuity’s biotechnology analyst, has a C$2 price target and a speculative buy rating.

Gonsalves comments, “As a clinical-stage biotechnology company, quarterly financials are not a materially impactful event, apart from unexpected variations in forecast cash burn.”

Operating expenses came in at $6.9 million, $900k above their $5.8 million estimate. The reason costs came in higher was due to R&D expenses, which were $5.3 million compared to the forecast of $3.9 million. General and administrative expenses however came below her estimate of $2 million. The company reported a net loss of $8.7 million, above Canaccord’s estimate of $7.2 million.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Gonsalves says that they are extending their estimate of when Phase 1b trial of their 118-MC addiction program to the fourth quarter of 2020 and now assuming phase 2 trial begins in 2021. She justifies this by stating, “there was no mention of completion in the financials.”

Onto Mind Medicine’s LSD microdose program, Gonsalves says that they continue to model for the trial to start in Q4/20 but adds, “it could be delayed to Q1/20. Phase 2 trials are expected to be complete by the end of 2022.”

With Mind Medicine expenses being over estimates, Tania has now increased her R&D expenses by $1.5 million in the fourth quarter and $1 million in 2021, “to account for Phase 1 trials slated to begin before year-end.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Red Cloud Fall Mining Showcase 2026 | Day 2

More Gold Without a Bigger Upfront Bill? | Keith Boyle – New Found Gold

The Red Cloud Fall Mining Showcase 2026 | Day 1

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Canaccord Initiates Coverage On Else Nutrition With C$6.50 Price Target

This morning, Canaccord Genuity initiated coverage on Else Nutrition (TSXV: BABY) with a C$6.50 price...

Monday, December 7, 2020, 04:26:00 PM

Valens Company Sees Haywood Lower Price Target To $4 After Q3 Results

Last week, The Valens Company (TSX: VLNS) reported their fiscal third quarter financial results. The...

Monday, October 18, 2021, 04:20:00 PM

Raymond James: Village Farms Expected To Post 15% Revenue Increase In Q3

Last night, Raymond James came out with their third quarter estimates for Village Farms (TSX:...

Friday, October 23, 2020, 10:50:08 AM

Enthusiast Gaming Sees Canaccord Reiterate $9.00 Price Target

On November 23rd, Enthusiast Gaming (TSX: EGLX) announced that they acquired Outplayed, Inc, the owners...

Saturday, November 27, 2021, 04:27:00 PM

Aurora Cannabis: Analysts Slash Price Targets Ahead Of Q4 Earnings

Tomorrow after market close Aurora Cannabis (TSX: ACB) (NYSE: ACB) will be reporting their fiscal...

Monday, September 21, 2020, 03:15:54 PM